This document is an excerpt from the EUR-Lex website
Document 62019CB0239
Case C-239/19: Order of the Court (Ninth Chamber) of 5 September 2019 (request for a preliminary ruling from the High Court of Justice (Chancery Division) – United Kingdom) — Eli Lilly and Company v Genentech Inc. (Reference for a preliminary ruling – Article 53(2) of the Rules of Procedure of the Court of Justice – Supplementary protection certificate for medicinal products – Regulation (EC) No 469/2009 – Article 3(b) – Conditions for obtaining – Marketing authorisation – Authorisation issued to a third party – Manifest inadmissibility)
Case C-239/19: Order of the Court (Ninth Chamber) of 5 September 2019 (request for a preliminary ruling from the High Court of Justice (Chancery Division) – United Kingdom) — Eli Lilly and Company v Genentech Inc. (Reference for a preliminary ruling – Article 53(2) of the Rules of Procedure of the Court of Justice – Supplementary protection certificate for medicinal products – Regulation (EC) No 469/2009 – Article 3(b) – Conditions for obtaining – Marketing authorisation – Authorisation issued to a third party – Manifest inadmissibility)
Case C-239/19: Order of the Court (Ninth Chamber) of 5 September 2019 (request for a preliminary ruling from the High Court of Justice (Chancery Division) – United Kingdom) — Eli Lilly and Company v Genentech Inc. (Reference for a preliminary ruling – Article 53(2) of the Rules of Procedure of the Court of Justice – Supplementary protection certificate for medicinal products – Regulation (EC) No 469/2009 – Article 3(b) – Conditions for obtaining – Marketing authorisation – Authorisation issued to a third party – Manifest inadmissibility)
OJ C 383, 11.11.2019, p. 35–36
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
11.11.2019 |
EN |
Official Journal of the European Union |
C 383/35 |
Order of the Court (Ninth Chamber) of 5 September 2019 (request for a preliminary ruling from the High Court of Justice (Chancery Division) – United Kingdom) — Eli Lilly and Company v Genentech Inc.
(Case C-239/19) (1)
(Reference for a preliminary ruling - Article 53(2) of the Rules of Procedure of the Court of Justice - Supplementary protection certificate for medicinal products - Regulation (EC) No 469/2009 - Article 3(b) - Conditions for obtaining - Marketing authorisation - Authorisation issued to a third party - Manifest inadmissibility)
(2019/C 383/39)
Language of the case: English
Referring court
High Court of Justice (Chancery Division)
Parties to the main proceedings
Applicant: Eli Lilly and Company
Defendant: Genentech Inc.
Operative part of the order
The request for a preliminary ruling from the High Court of Justice (England & Wales), Chancery Division (Patents Court) (United Kingdom), made by decision of 4 March 2019, is manifestly inadmissible.